Teucrium Corn Fund vs Regeneron Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $18.99 (market cap $125.39M), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 607.2× Teucrium Corn Fund's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Teucrium Corn Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Corn Fund for 26 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| CORN | REGN | |
|---|---|---|
Market Cap | $125.39M | $76.14B |
Volume | 271,634 | 500,239 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $20.29 | $852.03 |
52-Week Low | $16.46 | $557.73 |
Typical Hold Time | 26 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →